Ligand triggers of classical preconditioning and postconditioning

Cardiovascular Research

Volumn 70, Issue 2, 2006, Pages 212-221

  Gross, Eric R ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adenosine; Bradykinin; Opiods; Postconditioning; Preconditioning

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR; BISOPROLOL; BRADYKININ; CARVEDILOL; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; ERYTHROPOIETIN; FENTANYL ISOTHIOCYANATE; ISOPRENALINE; LOSARTAN; METOPROLOL; MORPHINE; MUSCARINIC RECEPTOR; OPIATE; RAMIPRILAT;

APOPTOSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM INJURY; ENZYME INHIBITION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; HEART VENTRICLE REMODELING; MOLECULAR MECHANICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; REPERFUSION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

ADENOSINE; ADRENERGIC AGENTS; BRADYKININ; CHOLINERGIC AGENTS; ERYTHROPOIETIN; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; LIGANDS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NARCOTICS; PROTEIN BINDING;

EID: 33646018367     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2005.12.019     Document Type: Review

References (119)

1. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
2. Zhao Z.Q., Corvera J.S., Halkos M.E., Kerendi F., Wang N.P., Guyton R.A., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 285 (2003) H579-H588
3. Gross E.R., Hsu A.K., and Gross G.J. Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. J Pharmacol Exp Ther 310 (2004) 185-191
4. Gross E.R., Peart J.N., Hsu A.K., Auchampach J.A., and Gross G.J. Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am J Physiol Heart Circ Physiol 288 (2005) H2744-H2749
5. Piper H.M., Abdallah Y., and Schafer C. The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61 (2004) 365-371
6. Vinten-Johansen J., Zhao Z.Q., Zatta A.J., Kin H., Halkos M.E., and Kerendi F. Postconditioning a new link in nature's armor against myocardial ischemia-reperfusion injury. Basic Res Cardiol 100 (2005) 295-310
7. Yellon D.M., and Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83 (2003) 1113-1151
8. Headrick J.P. Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine. J Mol Cell Cardiol 28 (1996) 1227-1240
9. Van Wylen D.G. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. Circulation 89 (1994) 2283-2289
10. Van Wylen D.G., Schmit T.J., Lasley R.D., Gingell R.L., and Mentzer Jr. R.M. Cardiac microdialysis in isolated rat hearts: interstitial purine metabolites during ischemia. Am J Physiol 262 (1992) H1934-H1938
11. Black Jr. R.G., Guo Y., Ge Z.D., Murphree S.S., Prabhu S.D., Jones W.K., et al. Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res 91 (2002) 165-172
12. Reichelt M.E., Willems L., Molina J.G., Sun C.X., Noble J.C., Ashton K.J., et al. Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance. Circ Res 96 (2005) 363-367
13. Guo Y., Bolli R., Bao W., Wu W.J., Black Jr. R.G., Murphree S.S., et al. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol 33 (2001) 825-830
14. Lee Y.M., Sheu J.R., and Yen M.H. BN-063, a newly synthesized adenosine A1 receptor agonist, attenuates myocardial reperfusion injury in rats. Eur J Pharmacol 279 (1995) 251-256
15. Smits G.J., McVey M., Cox B.F., Perrone M.H., and Clark K.L. Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 286 (1998) 611-618
16. Peart J., and Headrick J.P. Intrinsic, A(1) adenosine receptor activation during ischemia or reperfusion improves recovery in mouse hearts. Am J Physiol Heart Circ Physiol 279 (2000) H2166-H2175
17. Budde J.M., Velez D.A., Zhao Z., Clark K.L., Morris C.D., Muraki S., et al. Comparative study of AMP 579 and adenosine in inhibition of neutrophil-mediated vascular and myocardial injury during 24 h of reperfusion. Cardiovasc Res 47 (2000) 294-305
18. Norton E.D., Jackson E.K., Turner M.B., Virmani R., and Forman M.B. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am Heart J 123 (1992) 332-338
19. Norton E.D., Jackson E.K., Virmani R., and Forman M.B. Effect of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J 122 (1991) 1283-1291
20. Olafsson B., Forman M.B., Puett D.W., Pou A., Cates C.U., Friesinger G.C., et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76 (1987) 1135-1145
21. Pitarys C.J., Virmani R., Vildibill Jr. H.D., Jackson E.K., and Forman M.B. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation 83 (1991) 237-247
22. Velasco C.E., Turner M., Cobb M.A., Virmani R., and Forman M.B. Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine. Am Heart J 122 (1991) 1561-1570
23. Jordan J.E., Zhao Z.Q., Sato H., Taft S., and Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 280 (1997) 301-309
24. Goto M., Miura T., Iliodoromitis E.K., Leary O.'E.L., Ishimoto R., Yellon D.M., et al. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc Res 25 (1991) 943-949
25. Homeister J.W., Hoff P.T., Fletcher D.D., and Lucchesi B.R. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation 82 (1990) 595-608
26. Heide V.R.S., and Reimer K.A. Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs. Cardiovasc Res 31 (1996) 711-718
27. Xu Z., Downey J.M., and Cohen M.V. Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis 5 (2003) 368-371
28. Louttit J.B., Hunt A.A., Maxwell M.P., and Drew G.M. The time course of cardioprotection induced by GR79236, a selective adenosine A1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig. J Cardiovasc Pharmacol 33 (1999) 285-291
29. Baxter G.F., Hale S.L., Miki T., Kloner R.A., Cohen M.V., Downey J.M., et al. Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14 (2000) 607-614
30. Xu Z., Downey J.M., and Cohen M.V. Amp 579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors. J Cardiovasc Pharmacol 38 (2001) 474-481
31. Yang X.M., Krieg T., Cui L., Downey J.M., and Cohen M.V. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36 (2004) 411-421
32. Xu Z., Yang X.M., Cohen M.V., Neumann T., Heusch G., and Downey J.M. Limitation of infarct size in rabbit hearts by the novel adenosine receptor agonist AMP 579 administered at reperfusion. J Mol Cell Cardiol 32 (2000) 2339-2347
33. Kis A., Baxter G.F., and Yellon D.M. Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2. Cardiovasc Drugs Ther 17 (2003) 415-425
34. Lasley R.D., Jahania M.S., and Mentzer Jr. R.M. Beneficial effects of adenosine A(2a) agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 280 (2001) H1660-H1666
35. Schlack W., Schafer M., Uebing A., Schafer S., Borchard U., and Thamer V. Adenosine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol 22 (1993) 89-96
36. Maddock H.L., Mocanu M.M., and Yellon D.M. Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 283 (2002) H1307-H1313
37. Auchampach J.A., Ge Z.D., Wan T.C., Moore J., and Gross G.J. A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol Heart Circ Physiol 285 (2003) H607-H613
38. Cleveland Jr. J.C., Meldrum D.R., Rowland R.T., Banerjee A., and Harken A.H. Adenosine preconditioning of human myocardium is dependent upon the ATP-sensitive K+ channel. J Mol Cell Cardiol 29 (1997) 175-182
39. Liu G.S., Richards S.C., Olsson R.A., Mullane K., Walsh R.S., and Downey J.M. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 28 (1994) 1057-1061
40. Liu G.S., Thornton J., Van Winkle D.M., Stanley A.W., Olsson R.A., and Downey J.M. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation 84 (1991) 350-356
41. Tsuchida A., Miura T., Miki T., Shimamoto K., and Iimura O. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning. Cardiovasc Res 26 (1992) 456-461
42. Auchampach J.A., Jin X., Moore J., Wan T.C., Kreckler L.M., Ge Z.D., et al. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther 308 (2004) 846-856
43. Solenkova N.V., Cohen M.V., and Downey J.M. Ischemic preconditioning protects the heart through adenosine receptor activation during reperfusion. J Mol Cell Cardiol (2005) 848
44. Yang X.M., Philipp S., Downey J.M., and Cohen M.V. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100 (2005) 57-63
45. Kin H., Zatta A.J., Lofye M.T., Amerson B.S., Halkos M.E., Kerendi F., et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 67 (2005) 124-133
46. Baumgarten C.R., Linz W., Kunkel G., Scholkens B.A., and Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 108 (1993) 293-295
47. Pan H.L., Chen S.R., Scicli G.M., and Carretero O.A. Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning. Am J Physiol Heart Circ Physiol 279 (2000) H116-H121
48. Schulz R., Post H., Vahlhaus C., and Heusch G. Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 98 (1998) 1022-1029
49. Bhoola K.D., Elson C.J., and Dieppe P.A. Kinins-key mediators in inflammatory arthritis?. Br J Rheumatol 31 (1992) 509-518
50. Marceau F., Hess J.F., and Bachvarov D.R. The B1 receptors for kinins. Pharmacol Rev 50 (1998) 357-386
51. Tschope C., Heringer-Walther S., Koch M., Spillmann F., Wendorf M., Hauke D., et al. Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. J Hyperten 18 (2000) 223-228
52. Tschope C., Koch M., Spillmann F., Heringer-Walther S., Mochmann H.C., Stauss H., et al. Upregulation of the cardiac bradykinin B2 receptors after myocardial infarction. Immunopharmacology 44 (1999) 111-117
53. Yang X.P., Liu Y.H., Scicli G.M., Webb C.R., and Carretero O.A. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30 (1997) 735-740
54. Xu J., Carretero O.A., Sun Y., Shesely E.G., Rhaleb N.E., Liu Y.H., et al. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45 (2005) 747-753
55. Tio R.A., Tobe T.J., Bel K.J., Langen d.C.D., van Gilst W.H., and Wesseling H. Beneficial effects of bradykinin on porcine ischemic myocardium. Basic Res Cardiol 86 (1991) 107-116
56. Tobe T.J., de Langen C.D., Tio R.A., Bel K.J., Mook P.H., and Wesseling H. In vivo effect of bradykinin during ischemia and reperfusion: improved electrical stability two weeks after myocardial infarction in the pig. J Cardiovasc Pharmacol 17 (1991) 600-607
57. Yang X.P., Liu Y.H., Peterson E., and Carretero O.A. Effect of neutral endopeptidase 24.11 inhibition on myocardial ischemia/reperfusion injury: the role of kinins. J Cardiovasc Pharmacol 29 (1997) 250-256
58. Bell R.M., and Yellon D.M. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 35 (2003) 185-193
59. Wall T.M., Sheehy R., and Hartman J.C. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 270 (1994) 681-689
60. Leesar M.A., Stoddard M.F., Manchikalapudi S., and Bolli R. Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J Am Coll Cardiol 34 (1999) 639-650
61. Baxter G.F., and Ebrahim Z. Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br J Pharmacol 135 (2002) 843-854
62. Schriefer J.A., Broudy E.P., and Hassen A.H. Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model. J Pharmacol Exp Ther 278 (1996) 1034-1039
63. Hartman J.C., Wall T.M., Hullinger T.G., and Shebuski R.J. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 21 (1993) 996-1003
64. Liu Y.H., Yang X.P., Sharov V.G., Sigmon D.H., Sabbath H.N., and Carretero O.A. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 27 (1996) 7-13
65. Hartman J.C., Hullinger T.G., Wall T.M., and Shebuski R.J. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 234 (1993) 229-236
66. Romano M.A., Seymour E.M., Berry J.A., Nish McR.A., and Bolling S.F. Relative contribution of endogenous opioids to myocardial ischemic tolerance. J Surg Res 118 (2004) 32-37
67. Howells R.D., Kilpatrick D.L., Bailey L.C., Noe M., and Udenfriend S. Proenkephalin mRNA in rat heart. Proc Natl Acad Sci U S A 83 (1986) 1960-1963
68. Krumins S.A., Faden A.I., and Feuerstein G. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem Biophys Res Commun 127 (1985) 120-128
69. Ventura C., Bastagli L., Bernardi P., Caldarera C.M., and Guarnieri C. Opioid receptors in rat cardiac sarcolemma: effect of phenylephrine and isoproterenol. Biochim Biophys Acta 987 (1989) 69-74
70. Wittert G., Hope P., and Pyle D. Tissue distribution of opioid receptor gene expression in the rat. Biochem Biophys Res Commun 218 (1996) 877-881
71. Zhang W.M., Jin W.Q., and Wong T.M. Multiplicity of kappa opioid receptor binding in the rat cardiac sarcolemma. J Mol Cell Cardiol 28 (1996) 1547-1554
72. Bell S.P., Sack M.N., Patel A., Opie L.H., and Yellon D.M. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol 36 (2000) 2296-2302
73. Takasaki Y., Wolff R.A., Chien G.L., and van Winkle D.M. Met5-enkephalin protects isolated adult rabbit cardiomyocytes via delta-opioid receptors. Am J Physiol 277 (1999) H2442-H2450
74. Gross E.R., Hsu A.K., and Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 94 (2004) 960-966
75. Peart J.N., Patel H.H., and Gross G.J. Delta-opioid receptor activation mimics ischemic preconditioning in the canine heart. J Cardiovasc Pharmacol 42 (2003) 78-81
76. Schultz J.E., Hsu A.K., and Gross G.J. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 78 (1996) 1100-1104
77. Schultz J.J., Hsu A.K., and Gross G.J. Ischemic preconditioning and morphine-induced cardioprotection involve the delta (delta)-opioid receptor in the intact rat heart. J Mol Cell Cardiol 29 (1997) 2187-2195
78. Wang G.Y., Wu S., Pei J.M., Yu X.C., and Wong T.M. Kappa- but not delta-opioid receptors mediate effects of ischemic preconditioning on both infarct and arrhythmia in rats. Am J Physiol Heart Circ Physiol 280 (2001) H384-H391
79. Tomai F., Crea F., Gaspardone A., Versaci F., Ghini A.S., Ferri C., et al. Effects of naloxone on myocardial ischemic preconditioning in humans. J Am Coll Cardiol 33 (1999) 1863-1869
80. Chien G.L., and Van Winkle D.M. Naloxone blockade of myocardial ischemic preconditioning is stereoselective. J Mol Cell Cardiol 28 (1996) 1895-1900
81. Kin H., Zatta A.J., Jiang R., Reeves J.G., Mykytenko J., Sorescu G., et al. Activation of opioid receptors mediates the infarct size reduction by postconditioning. J Mol Cell Cardiol 38 (2005) 827
82. Namiuchi S., Kagaya Y., Ohta J., Shiba N., Sugi M., Oikawa M., et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 45 (2005) 1406-1412
83. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 100 (2003) 4802-4806
84. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
85. Lipsic E., van der Meer P., Henning R.H., Suurmeijer A.J., Boddeus K.M., vanVeldhuisen D.J., et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44 (2004) 473-479
86. Parsa C.J., Kim J., Riel R.U., Pascal L.S., Thompson R.B., Petrofski J.A., et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279 (2004) 20655-20662
87. Bullard A.J., Govewalla P., and Yellon D.M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol (2005)
88. Hirata A., Minamino T., Asanuma H., Sanada S., Fujita M., Tsukamoto O., et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 19 (2005) 33-40
89. Tramontano A.F., Muniyappa R., Black A.D., Blendea M.C., Cohen I., Deng L., et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 308 (2003) 990-994
90. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., and Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18 (2004) 1031-1033
91. Broadley K.J., and Penson P.E. The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia. Auton Autacoid Pharmacol 24 (2004) 87-93
92. Tong H., Bernstein D., Murphy E., and Steenbergen C. The role of beta-adrenergic receptor signaling in cardioprotection. FASEB J 19 (2005) 983-985
93. Cross H.R., Steenbergen C., Lefkowitz R.J., Koch W.J., and Murphy E. Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. Circ Res 85 (1999) 1077-1184
94. LaBruno S., Naim K.L., Li J.K., Drzewiecki G., and Kedem J. Beta-adrenergic stimulation of reperfused myocardium after 2-hour ischemia. J Cardiovasc Pharmacol 32 (1998) 535-542
95. Feuerstein G., Liu G.L., Yue T.L., Cheng H.Y., Hieble J.P., Arch J.R., et al. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur J Pharmacol 351 (1998) 341-350
96. Gao F., Chen J., Lopez B.L., Christopher T.A., Gu J., Lysko P., et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 406 (2000) 109-116
97. Bankwala Z., Hale S.L., and Kloner R.A. Alpha-adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning. Circulation 90 (1994) 1023-1028
98. Banerjee A., Locke-Winter C., Rogers C., Mitchell K.B., Brew M.B., Cairns E.C., et al. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an alpha 1-adrenergic mechanism. Circ Res 73 (1993) 656-670
99. Iliodromitis E.K., Tasouli A., Andreadou I., Bofilis E., Zoga A., Cokkinos P., et al. Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo. Eur J Pharmacol 499 (2004) 163-169
100. Kawada T., Yamazaki T., Akiyama T., Mori H., Inagaki M., Shishido T., et al. Effects of brief ischaemia on myocardial acetylcholine and noradrenaline levels in anaesthetized cats. Auton Neurosci 95 (2002) 37-42
101. Yao Z., and Gross G.J. Acetylcholine mimics ischemic preconditioning via a glibenclamide-sensitive mechanism in dogs. Am J Physiol 264 (1993) H2221-H2225
102. Yao Z., and Gross G.J. Role of nitric oxide, muscarinic receptors, and the ATP-sensitive K+ channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ Res 73 (1993) 1193-1201
103. Thornton J.D., Thornton C.S., and Downey J.M. Effect of adenosine receptor blockade: preventing protective preconditioning depends on time of initiation. Am J Physiol 265 (1993) H504-H508
104. Richard V., Blanc T., Kaeffer N., Tron C., and Thuillez C. Myocardial and coronary endothelial protective effects of acetylcholine after myocardial ischaemia and reperfusion in rats: role of nitric oxide. Br J Pharmacol 115 (1995) 1532-1538
105. Gumina R.J., Buerger E., Eickmeier C., Moore J., Daemmgen J., and Gross G.J. Inhibition of the Na(+)/H(+) exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs. Circulation 100 (1999) 2519-2526 [discussion 2469-72]
106. Breitwieser G.E. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ Res 94 (2004) 17-27
107. Kato R., and Foex P. Fentanyl reduces infarction but not stunning via delta-opioid receptors and protein kinase C in rats. Br J Anaesth 84 (2000) 608-614
108. Peart J.N., and Gross G.J. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol 285 (2003) H81-H89
109. Asanuma H., Minamino T., Sanada S., Takashima S., Ogita H., Ogai A., et al. Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation 109 (2004) 2773-2779
110. Shan J., Yu X.C., Fung M.L., and Wong T.M. Attenuated "cross talk" between kappa-opioid receptors and beta-adrenoceptors in the heart of chronically hypoxic rats. Pflugers Arch 444 (2002) 126-132
111. Cohen M.V., Baines C.P., and Downey J.M. Ischemic preconditioning: from adenosine receptor to KATP channel. Annu Rev Physiol 62 (2000) 79-109
112. Hausenloy D.J., Tsang A., and Yellon D.M. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15 (2005) 69-75
113. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 61 (2004) 448-460
114. Murphy E., and Steenbergen C. Inhibition of GSK-3beta as a target for cardioprotection: the importance of timing, location, duration and degree of inhibition. Expert Opin Ther Targets 9 (2005) 447-456
115. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., et al. Erk associates with and primes GSK-3beta for its inactivation resulting upregulation of beta-catenin. Mol Cell 19 (2005) 159-170
116. Juhaszova M., Zorov D.B., Kim S.H., Pepe S., Fu Q., Fishbein K.W., et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113 (2004) 1535-1549
117. Tong H., Imahashi K., Steenbergen C., and Murphy E. Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase-dependent pathway is cardioprotective. Circ Res 90 (2002) 377-379
118. Hausenloy D.J., Duchen M.R., and Yellon D.M. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 60 (2003) 617-625
119. Cohen M.V., Yang X.M., Liu G.S., Heusch G., and Downey J.M. Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. Circ Res 89 (2001) 273-278